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cositis can contribute to increased length of stay during stem cell
transplantation. The purpose of this study is to compare patients
who received Kepivance® (palifermin) as part of their treatment
with patients who did not receive this medication regimen during
autologous stem cell transplantation. We performed a retrospec-
tive analysis of 40 patients; 20 prior to the institution of Kepiv-
ance® (palifermin), and 20 patients after. The preparative regimens
include Melphalan, Busulfan and Etoposide and Etoposide and
Cytoxan and BCNU and Etoposide. The average length of stay for
non-Kepivance patients was 32.3 days compared to 28.3 days in
patients who received the drug. The severity of both oral and GI
mucositis appeared to be less. Seventeen out of 20 non-Kepivance
patients experienced diarrhea or rectal irritation versus 9 out of 20
with Kepivance. Neutropenic fever was prevalent in both groups.
There was a trend toward earlier engraftment in the Kepivance
group. Kepivance seems to have had a positive effect for our
patients. This pilot study suggests an improvement in mucositis
symptoms with the use of Kepivance® (palifermin). It appears that
mucositis and its treatment contribute to the length of stay and
costs of stem cell transplantation. Quality of life for these patients
can be greatly improved if mucositis is eliminated or reduced
during the course of stem cell transplantation.
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HERTH HOPE SCALE ASSESSMENT IN SCCA TRANSPLANT PATIENTS
Rochester, J.M.1, Berry, D.L.1 Seattle Cancer Care Alliance, Seattle,
WA.
Significance: In order to help patients maintain or restore hope,
nurses nurture and promote hope. They help patients seek out
accurate information for a path to a better future. No efﬁcient or
systemic method has been applied in the transplant setting to date.
The Herth Hope Scale has been used in the context of homeless
families, older adults in the community and institutional settings,
in terminally ill patients, and people with ﬁrst recurrence of cancer.
Objective: Describe distribution of scores on the Herth Hope
Scale in a convenient sample of transplant patients. Eligibility:
Autologous Hematopoietic Stem Cell Transplant Patients. Meth-
ods: In a convenience sample of 30 patients, the Herth Hope Scale
was offered as a clinical assessment tool. Patients answered the
questionnaire on paper. No identiﬁers were recorded on the tool
nor were the results linked in any way to the patients’ records or
other data. The Herth Hope Scale data will be entered and ana-
lyzed with descriptive statistics in order to evaluate the score
distribution. This is an ongoing study through December 2005,
with the ﬁnal results in February 2006.
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PARTIAL MATURATION AND ROBUST EX VIVO EXPANSION OF UMBIL-
ICAL CORD BLOOD (UCB) T CELLS: A STEP TOWARDS ADOPTIVE
IMMUNOTHERAPY AFTER UCB TRANSPLANTS
Mazur, M.A.1, Lee, Y.A.1, Kurtzburg, J.1, Szabolcs, P.1 Duke Uni-
versity Medical Center Pediatric Blood and Bone Marrow Transplant,
Durham, NC.
Background: Viral infections cause signiﬁcant morbidity and
mortality in patients receiving unrelated umbilical cord blood
(uUCB) transplants as there is no established antiviral immunity in
naive UCB lymphocytes available for adoptive transfer. Addition-
ally, UCB T cells lack Th1/Tc1 cytokines, granzymes, and per-
forin, which are prerequisites to control viral pathogens. Another
limitation of UCB transplantation is the unavailability of donor T
cells for post-transplant donor leukocyte infusions (DLI) to boost
immunity or induce GVL. Still, a small fraction of the UCB graft
could be set aside for ex vivo T cell expansion. We tested the
hypothesis that UCB T cells could be expanded to cell doses
suitable for DLI and that they may mature acquiring a phenotype
compatible with effector function as assessed by expression of key
cytokines and members of the granzyme-perforin pathway. Meth-
ods: Thawed UBC research samples with a T cell content 3% of
an average UCB graft were processed. T cells were puriﬁed with
“EasySep” (StemCell Technologies) and 5–11  105 T cells/ml
were incubated in gas permeable bags with “CD3/28 T cell Ex-
pander” artiﬁcial APC beads (Dynal) in 10% human serum replete
media  200u/ml IL-2. Media and cytokines were replenished 3
times per week to maintain a concentration of  2  106 cells/ml.
Results: After 14 days UCB T cells expanded 72 fold  39 (mean,
SD), n  9. There was signiﬁcant evolution in phenotype over this
time (Table 1) with up to 40% of T cells entering the cell cycle
(Ki-67). The majority of expanded cells have acquired the phe-
notype of activated (HLA-DR, CD25, CD45RO) memory
cells, at the expense of naive/recent thymic immigrants
(CD45RA/CD62L). The CD4/CD8 ratio became inverted due
to the higher expansion rate of CD8 T cells (P  .0078) with no
difference in apoptosis (activated Casp-3, P  .188). Notably, all
T cells retained expression of CD28 and CD27. Granzymes A and
B and cytokine expression was acquired during expansion but
remained below normal adult peripheral blood values. However,
effector cytotoxic T cells with perforin or CD57 expression were
undetected. Conclusions: From our results we can demonstrate
effective expansion and partial maturation of UCB T Cells. Start-
ing with 2  106 total T cells, 73-fold expansion could provide for
DLI 6  106 T cells/kg for an average pediatric patient (25 kg).
In summary, ex vivo expansion could provide clinically relevant
number of partially mature T cells for adoptive immunotherapy
(Table 1).
Table 1. Characterization of Expanded T Cells as % of all Lymphocytes
Variable Median SD
CD3 99.8 0.4
CD4 38.7 9.3
CD4/CD8 2.3 2.3
CD28 98 6.9
CD45RA/RO 8.5 14.9
CD45RO/RA 47.8 23.4
CD25 57.2 22.2
CD45RA/CD62 54.5 22.7
CD45RA/CD27/CD8 59 16.4
CD45RA/CD27/CD8 39.4 17.2
KI67/CD8 38.8 11
KI67/CD4 30.4 11.4
HLA DR 39.3 17.5
Granzyme A/CD8 48 17
Granzyme B/CD8 4.9 4.2
Perforin/CD8 0 0
INF/CD3 1.9 5.6
TNF	/CD3 6.7 25.4
IL2/CD3 5.4 13.9
IL4/CD3 0 0
Act Caspase 3/CD4 11.7 8.9
Act Caspase 3/CD8 12.3 14.3
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) USING UM-
BILICAL CORD BLOOD UNITS (UCB) NOT DEPLETED OF RED BLOOD
CELLS PRIOR TO CRYOPRESERVATION
Chow, R.1, Nademanee, A.2, Rosenthal, J.2, Karanes, C.2,
Jaing, T.-H.3, Tan, P.4, Graham, M.5, Gjertson, D.6, Petz, L.1 1.
StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. Chung Gung Memorial
Hospital, Linko, Taiwan; 4. Mount Elizabeth Hospital, Singapore, Sin-
gapore; 5. University of Arizona Medical Center, Tuscon, AZ; 6. UCLA
Medical Center, Los Angeles, CA.
UCB is a promising source for HSCT; however, limiting cell
dose has hampered its widespread use. The red cell depletion
(RCD) techniques that are widely used incur signiﬁcant nucleated
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